Key Details
Price
$465.99Annual ROE
22.99%Beta
0.64Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 05, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Aug 24, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Do you have $500? Here's one biotech stock you should consider buying and keeping for the long term.
Biotech company Vertex Pharmaceuticals (VRTX) has faced challenges in the stock market recently, affecting its 10% gain for the year. After a 5.6% increase following its earnings report earlier this month, the stock has lost that momentum and is now at its lowest point since June.
Lately, users of Zacks.com have been focusing on Vertex (VRTX). This interest prompts a closer look at what the stock might offer.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 9:00 AM ET. The company will be represented by Dr. Reshma Kewalramani, who is the President and CEO. Debjit Chattopadhyay from Guggenheim Partners will host the event and welcome Dr. Kewalramani.
Regulators are examining a drug that has the potential to be worth billions of dollars.
Vertex Pharmaceuticals (VRTX) has hit an important support level, making it an attractive option for investors based on technical analysis. The stock recently surpassed the 20-day moving average, indicating a positive trend in the short term.
From a technical viewpoint, Vertex Pharmaceuticals (VRTX) appears to be an appealing choice since it has just hit an important support level. VRTX has recently surpassed the 50-day moving average, indicating a positive trend in the short term.
The main figures for Vertex (VRTX) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be helpful to look at some of its important metrics in relation to Wall Street predictions and last year's results.
Vertex Pharmaceuticals (VRTX) finished the most recent trading session at $476.37, which is a decrease of 0.28% compared to the previous day.
This stock may not stay below $500 for much longer.
FAQ
- What is the primary business of Vertex Pharmaceuticals Incorporated?
- What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
- Does Vertex Pharmaceuticals Incorporated pay dividends?
- What sector is Vertex Pharmaceuticals Incorporated in?
- What industry is Vertex Pharmaceuticals Incorporated in?
- What country is Vertex Pharmaceuticals Incorporated based in?
- When did Vertex Pharmaceuticals Incorporated go public?
- Is Vertex Pharmaceuticals Incorporated in the S&P 500?
- Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?
- Is Vertex Pharmaceuticals Incorporated in the Dow Jones?
- When was Vertex Pharmaceuticals Incorporated's last earnings report?
- When does Vertex Pharmaceuticals Incorporated report earnings?
- Should I buy Vertex Pharmaceuticals Incorporated stock now?